PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics

Rhea-AI Summary

PetVivo (OTCQX: PETV) announced a Vendor Partner Agreement with Veterinary Growth Partners (VGP) on October 16, 2025 to expand commercial access to its veterinary therapeutics.

Under the agreement VGP — which serves over 7,300 veterinary members — will promote PetVivo’s flagship products Spryng with OsteoCushion Technology and PrecisePRP across its network, streamlining purchasing and access for member practices. PrecisePRP is an off-the-shelf, leucoreduced allogeneic PRP product with 4 billion platelets per vial (500,000 platelets/μL) and <1500 WBC/μL. The agreement aims to accelerate national availability and product adoption for non-pharmaceutical regenerative treatments.

Insights

Veterinary Commercial Strategist

Partnership with a 7,300‑member MSO broadens national access to PetVivo's injectable and off‑the‑shelf regenerative products.

PetVivo gains a clear commercial channel through Veterinary Growth Partners, which serves over 7,300 practices. The Agreement makes Spryng® with OsteoCushion® Technology and PrecisePRP® available via VGP's vendor network, simplifying procurement and promoting adoption of minimally invasive intra‑articular treatments for joint conditions in dogs and horses.

Key dependencies include VGP's active promotion and member uptake; success requires clinic-level training, reimbursement clarity, and supply logistics to match demand. The product specs disclosed — a consistent dose of 4 billion platelets per vial at 500,000 platelets/µL and leucoreduction to <1500 WBCs/µL — support a value proposition of uniformity and convenience versus point-of-care kits.

Watch adoption and distribution metrics over the next 6–18 months, including the number of VGP member practices placing initial orders, training completion rates, and any reported clinical usage patterns or adverse events. Monitor product availability and any updates to practice-level purchasing terms around Oct. 16, 2025.

MINNEAPOLIS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW) and an emerging biomedical device company focused on the commercialization of groundbreaking medical products for horses and companion animals, today announced it has entered into a Vendor Partner Agreement (“Agreement”) with Veterinary Growth Partners (“VGP”). Veterinary Growth Partners is a management services organization (MSO) that supports veterinary practices by offering practice management and marketing tools, consulting, and vendor relationships to help them improve efficiency, profitability, and operations. Veterinary Growth Partners serves more than over 7,300 veterinary members across the United States.

Under the agreement, Veterinary Growth Partners will actively promote PetVivo’s flagship products — Spryng^® with OsteoCushion^® Technology and PrecisePRP^® — to its expansive member network. These products provide veterinarians with innovative, minimally invasive treatment options for managing joint-related conditions and assisting in the enhancement of musculoskeletal restoration in companion animals. The completion of this Agreement now provides Veterinary Growth Partners’ member practices streamlined and value-added access to Spryng and PrecisePRP.

SPRYNG with OsteoCushion Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (“PRP”) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP^™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP^® guarantees. Each vial of PrecisePRP^® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.

“We are excited to partner with Veterinary Growth Partners and bring our cutting-edge therapeutics to an even wider base of veterinary professionals,” said John Lai, Chief Executive Officer of PetVivo Animal Health, Inc. “With VGP’s trusted industry position and extensive reach, this collaboration significantly accelerates our mission to improve the quality of life for animals through advanced science and accessible treatment solutions.”

“PetVivo’s products align with VGP’s commitment to delivering proven, forward-thinking solutions that empower veterinary practices,” said Rob Sigman, CEO of Veterinary Growth Partners. “We believe Spryng and PrecisePRP will make a meaningful impact in orthopedic and regenerative treatment protocols across our member network.”

The Vendor Partner Agreement is expected to expand national availability, accelerate product adoption, and enhance purchasing efficiency for veterinary practices seeking non-pharmaceutical and regenerative solutions for their patients.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG with OsteoCushion technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.

About Veterinary Growth Partners
Veterinary Growth Partners (VGP) is a management services organization specializing in empowering members to reach their practices' full potential. VGP offers an extensive range of services, including business consulting, training, education, negotiated vendor contracts, technology solutions, networking opportunities, and performance metrics and benchmarking.

CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216

Rob Sigman
Veterinary Growth Partners
211 Walter Seaholm Dr Suite 200
Austin, TX 78701
1-800-577-0120

Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

FAQ

What did PetVivo (PETV) announce on October 16, 2025?

PetVivo announced a Vendor Partner Agreement with Veterinary Growth Partners to promote Spryng and PrecisePRP across VGP’s member network.

How many veterinary practices does Veterinary Growth Partners reach for PetVivo (PETV)?

VGP serves more than 7,300 veterinary members across the United States, which the agreement makes accessible to PetVivo products.

What are the key product specifications of PrecisePRP mentioned by PetVivo (PETV)?

Each vial contains a consistent dose of 4 billion platelets at 500,000 platelets/μL and is leucoreduced with <1500 white blood cells/μL.

What clinical applications does Spryng with OsteoCushion target for PetVivo (PETV)?

Spryng is an intra-articular injectable intended to aid management of noninfectious joint pain, including joint instability, degenerative joint disease and osteoarthritis.

How will the PetVivo (PETV)–VGP agreement affect product availability and adoption?

The agreement is expected to expand national availability, accelerate product adoption, and improve purchasing efficiency for veterinary practices.